Show simple item record

dc.contributor.authorSaiyed, Mohd Masnoon
dc.contributor.authorOng, Pei Shi
dc.contributor.authorChew, Lita
dc.date.accessioned2021-08-05T06:34:49Z
dc.date.available2021-08-05T06:34:49Z
dc.date.issued2017
dc.identifier.issn1759-8885
dc.identifier.doi10.1111/jphs.12175
dc.identifier.urihttp://hdl.handle.net/10072/406634
dc.description.abstractObjectives: Prescribing drugs outside regulatory recommendation is known as off-label use. Studies have reported widespread off-label drug use in oncology practice. But the clinical, economic and humanistic outcomes for such practice are often uncertain. Hence, it is important to gather oncology practitioners’ perspective for the creation of clinical practice framework and policies. The aim of the study was to evaluate perception of oncology practitioners on off-label use in cancer therapy. Methods: This study employed a cross-sectional design implemented in the form of the self-administered questionnaire at National Cancer Centre Singapore where more than 50% cancer patients of the country are treated. Key findings: Eighty-one practitioners involving nurses (38%), medical oncologist (37%) and pharmacists (25%) were surveyed. The majority of practitioners (57%) agreed off-label use as indispensable practice in cancer therapy. Main reasons cited include advanced cancers where standard lines of treatment are exhausted (58%), lack of alternative approved drug (43%) and rare tumours (47%). Compared with other practitioners, medical oncologists viewed Phase 2 (73% versus 31%, P = 0.001) and conference abstracts (56% versus 23%, P = 0.003) as reasonable evidence for off-label use. Major concerns included lack of efficacy (58%), patient understanding (47%), uncertain safety (43%) and out-of-pocket cost (41%) associated with off-label use. Most viewed need for obtaining informed consent (86%) and institutional guidance (75%) as important elements in practice framework. Conclusion: The study provides insights about off-label drug use practice and establishes the need for robust clinical guidance and educational strategies for oncology practitioners.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherWILEY
dc.relation.ispartofpagefrom91
dc.relation.ispartofpageto99
dc.relation.ispartofissue2
dc.relation.ispartofjournalJournal of Pharmaceutical Health Services Research
dc.relation.ispartofvolume8
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4206
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsHealth Care Sciences & Services
dc.subject.keywordsclinical practice
dc.subject.keywordsoff-label drug use
dc.titlePerception of oncology practitioners towards off-label use of anticancer medicines in Singapore
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSaiyed, MM; Ong, PS; Chew, L, Perception of oncology practitioners towards off-label use of anticancer medicines in Singapore, Journal of Pharmaceutical Health Services Research, 2017, 8 (2), pp. 91-99
dc.date.updated2021-08-05T06:33:03Z
gro.hasfulltextNo Full Text
gro.griffith.authorSaiyed, Masnoon


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record